GALANTAMINE ER CAPSULE (EXTENDED RELEASE)
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
23-06-2017
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
から入手可能:
SANIS HEALTH INC
ATCコード:
N06DA04
INN（国際名）:
GALANTAMINE
投薬量:
16MG
医薬品形態:
CAPSULE (EXTENDED RELEASE)
構図:
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
治療領域:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
製品概要:
Active ingredient group (AIG) number: 0144660004; AHFS:
認証ステータス:
APPROVED
承認日:
2016-01-07
製品の特徴
Page 1 of 55
PRODUCT MONOGRAPH
PR
GALANTAMINE ER
Galantamine Hydrobromide Extended-Release Capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
SANIS HEALTH INC.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision: June 22, 2017
Submission Control No: 206599
Page 2 of 55
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.........................................................................
25
CLINICAL TRIALS
.........................................................................................................
26
DETAILED PHARMACOLOGY
..............................................
完全なドキュメントを読む
